These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 3284069

  • 1. Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model.
    Vogelsang GB, Wells MC, Santos GW, Chen TL, Hess AD.
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):226-8. PubMed ID: 3284069
    [No Abstract] [Full Text] [Related]

  • 2. Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants.
    Truog AW, Wozniak SP.
    Oncol Nurs Forum; 1990 Apr; 17(1):39-44. PubMed ID: 2405360
    [Abstract] [Full Text] [Related]

  • 3. Combination of cyclosporine and methotrexate for prophylaxis of acute graft versus host disease after allogeneic bone marrow transplantation for leukaemias.
    Mrsić M, Labar B, Bogdanić V, Nemet D, Pavletić Z, Plavsić F, Dobrić I, Kastelan A, Marusić M, Zupancić-Salek S.
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():95-6. PubMed ID: 2697416
    [No Abstract] [Full Text] [Related]

  • 4. [Thalidomide 1989].
    Codina C.
    Med Clin (Barc); 1989 Apr 22; 92(15):571-2. PubMed ID: 2666770
    [No Abstract] [Full Text] [Related]

  • 5. Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids.
    Ruutu T, Volin L, Elonen E.
    Transplant Proc; 1988 Jun 22; 20(3):491-3. PubMed ID: 3289191
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL, Bloom EJ.
    Clin Pharm; 1993 Oct 22; 12(10):736-61. PubMed ID: 8258255
    [Abstract] [Full Text] [Related]

  • 7. Decreased incidence of graft-versus-host disease in bone marrow transplantation recipients treated with a combination of cyclosporine and methotrexate.
    Tollemar J, Ringdén O, Sundberg B, Bolme P, Brattström C, Gahrton G, Johansen L, Lönnqvist B.
    Transplant Proc; 1988 Jun 22; 20(3):494-8. PubMed ID: 3381257
    [No Abstract] [Full Text] [Related]

  • 8. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
    Gluckman E, Devergie A, Lokiec F.
    Transplant Proc; 1988 Jun 22; 20(3 Suppl 3):461-9. PubMed ID: 3291282
    [No Abstract] [Full Text] [Related]

  • 9. Combination prophylactic immunosuppression in bone marrow transplantation.
    Szer J.
    Transplant Proc; 1989 Feb 22; 21(1 Pt 3):3011-2. PubMed ID: 2650415
    [No Abstract] [Full Text] [Related]

  • 10. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM, Omdal BK, Dai KZ, Martens A, Benestad HB, Vaage JT, Rolstad B.
    Transplantation; 2008 Jan 15; 85(1):102-11. PubMed ID: 18192919
    [Abstract] [Full Text] [Related]

  • 11. Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate.
    Tollemar J, Ringdén O, Heimdahl A, Lönnqvist B, Sundberg B.
    Transplant Proc; 1988 Jun 15; 20(3 Suppl 3):470-9. PubMed ID: 3291283
    [No Abstract] [Full Text] [Related]

  • 12. Thalidomide induction of bone marrow transplantation tolerance.
    Vogelsang GB, Hess AD, Gordon G, Brundrette R, Santos GW.
    Transplant Proc; 1987 Feb 15; 19(1 Pt 3):2658-61. PubMed ID: 3547944
    [No Abstract] [Full Text] [Related]

  • 13. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation--combination protocol of high dose methylprednisolone, prednisolone and methotrexate].
    Shinohara Y, Kai S, Misawa M, Fujimori Y, Okamoto T, Kohsaki M, Kanamaru A, Ifuku H, Ohe Y, Hara H.
    Rinsho Ketsueki; 1986 Jan 15; 27(1):30-5. PubMed ID: 3520045
    [No Abstract] [Full Text] [Related]

  • 14. Syngeneic graft-versus-host disease after allogeneic bone marrow transplantation and cyclosporine treatment.
    Hess AD, Vogelsang GB, Silanskis M, Friedman KA, Beschorner WE, Santos GW.
    Transplant Proc; 1988 Jun 15; 20(3 Suppl 3):487-92. PubMed ID: 3291285
    [No Abstract] [Full Text] [Related]

  • 15. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
    Russell JA, Woodman RC, Poon MC, Jones AR, Ruether BA.
    Bone Marrow Transplant; 1994 Sep 15; 14(3):397-401. PubMed ID: 7994261
    [Abstract] [Full Text] [Related]

  • 16. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, Sotto JJ, Guyotat D, Fière D, Archimbaud E.
    Bone Marrow Transplant; 1999 Jan 15; 23(2):145-50. PubMed ID: 10197799
    [Abstract] [Full Text] [Related]

  • 17. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL, Stainer C, Hyde H, Miflin G, Haynes AP, Bessell EM, Russell NH.
    Bone Marrow Transplant; 1998 Sep 15; 22(6):541-5. PubMed ID: 9758340
    [Abstract] [Full Text] [Related]

  • 18. A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplantation.
    Biggs JC, Atkinson K, Gillett E, Downs K, Concannon A, Dodds A.
    Transplant Proc; 1986 Apr 15; 18(2):253-5. PubMed ID: 3515659
    [No Abstract] [Full Text] [Related]

  • 19. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation.
    Cole CH, Rogers PC, Pritchard S, Phillips G, Chan KW.
    Bone Marrow Transplant; 1994 Dec 15; 14(6):937-42. PubMed ID: 7711671
    [Abstract] [Full Text] [Related]

  • 20. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
    Benekli M, Hahn T, Williams BT, Cooper M, Roy HN, Wallace P, Stewart C, Bambach B, McCarthy PL.
    Bone Marrow Transplant; 2006 Sep 15; 38(5):365-70. PubMed ID: 16862164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.